SIGLEC1 and breast carcinoma: In summary, for lymph node CD169+ macrophages in breast cancer patients, our data indicate that LNM enables a metastatic niche inducing loss of SCS CD169+ macrophages and change of MS CD169+ macrophage phenotype into more immunosuppressive cells, hence modulating the local lymph node anti-tumor immune milieu.